{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:53:55Z","timestamp":1784876035641,"version":"3.55.0"},"reference-count":27,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,19]]},"DOI":"10.20945\/2359-3997000000459","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T12:32:08Z","timestamp":1650457928000},"source":"Crossref","is-referenced-by-count":10,"title":["Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-306X","authenticated-orcid":false,"given":"Luciana Pinto","family":"Valadares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-7299","authenticated-orcid":false,"given":"Bruno Silva de Ara\u00fajo","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8613-723X","authenticated-orcid":false,"given":"Bernardo Matos da","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1639-306X","authenticated-orcid":false,"given":"Larissa Aniceto","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4638-0371","authenticated-orcid":false,"given":"Frederico Gideoni Albinati","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0446-338X","authenticated-orcid":false,"given":"Cristiane da Fonseca","family":"Hottz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-5861","authenticated-orcid":false,"given":"Gabriel Galv\u00e3o Rafael","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"2","key":"key20220420083155_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous Dysplasia\/McCune-Albright Syndrome: A Rare, Mosaic Disease of G\u03b1 s Activation","volume":"41","author":"Boyce","year":"2020","unstructured":"1 Boyce AM, Collins MT. Fibrous Dysplasia\/McCune-Albright Syndrome: A Rare, Mosaic Disease of G\u03b1 s Activation. Endocr Rev. 2020;41(2):1-26.","journal-title":"Endocr Rev"},{"issue":"6","key":"key20220420083155_B2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000504802","article-title":"The Clinical Spectrum of McCune-Albright Syndrome and Its Management","volume":"92","author":"Spencer","year":"2019","unstructured":"2 Spencer T, Pan KS, Collins MT, Boyce AM. The Clinical Spectrum of McCune-Albright Syndrome and Its Management. Horm Res Paediatr. 2019; 92(6):347-56.","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"key20220420083155_B3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00223-019-00550-z","article-title":"Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review","volume":"104","author":"Hartley","year":"2019","unstructured":"3 Hartley I, Zhadina M, Collins MT, Boyce AM. Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review. Calcif Tissue Int. 2019;104(5):517-29.","journal-title":"Calcif Tissue Int"},{"key":"key20220420083155_B4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1359\/jbmr.06s224","article-title":"Fibrous dysplasia as a stem cell disease","author":"Riminucci","year":"2006","unstructured":"4 Riminucci M, Saggio I, Robey PG, Bianco P. Fibrous dysplasia as a stem cell disease. J Bone Miner Res. 2006;21 Suppl 2:125-31.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20220420083155_B5","first-page":"1","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: A consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","unstructured":"5 Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, et al. Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: A consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis. 2019;14(1):1-17.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"key20220420083155_B6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","unstructured":"6 Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment. Bone. 2004;35(1):235-42.","journal-title":"Bone"},{"issue":"1","key":"key20220420083155_B7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4158\/EP-2018-0328","article-title":"Efficacy and safety of bisphosphonate therapy in mccune-albright syndrome\u2013related polyostotic fibrous dysplasia: A single-center experience","volume":"25","author":"Wang","year":"2019","unstructured":"7 Wang Y, Wang O, Jiang Y, Li M, Xia W, Meng X, et al. Efficacy and safety of bisphosphonate therapy in mccune-albright syndrome\u2013related polyostotic fibrous dysplasia: A single-center experience. Endocr Pract. 2019;25(1):23-30.","journal-title":"Endocr Pract"},{"key":"key20220420083155_B8","doi-asserted-by":"crossref","first-page":"115784","DOI":"10.1016\/j.bone.2020.115784","article-title":"Bisphosphonates for the treatment of fibrous dysplasia of bone","volume":"143","author":"Chapurlat","year":"2021","unstructured":"8 Chapurlat R, Legrand MA. Bisphosphonates for the treatment of fibrous dysplasia of bone. Bone. 2021;143:115784.","journal-title":"Bone"},{"issue":"4","key":"key20220420083155_B9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00223-013-9829-0","article-title":"Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia","volume":"94","author":"Thomsen","year":"2014","unstructured":"9 Thomsen MD, Rejnmark L. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Calcif Tissue Int. 2014;94(4):384-95.","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"key20220420083155_B10","first-page":"504","article-title":"Fibrous dysplasia & McCune-Albright syndrome: An experience from a tertiary care centre in north India Sanjay","volume":"133","author":"Bhadada","year":"2011","unstructured":"10 Bhadada SK, Bhansali A, Das S, Singh R, Sen R, Agarwal A, et al. Fibrous dysplasia & McCune-Albright syndrome: An experience from a tertiary care centre in north India Sanjay. Indian J Med Res. 2011;133(5):504-9.","journal-title":"Indian J Med Res"},{"key":"key20220420083155_B11","volume-title":"GeneReviews [Internet]","author":"Boyce","year":"2015","unstructured":"11 Boyce AM, Florenzano P, Castro LF, Collins MT. Fibrous Dysplasia\/McCune-Albright Syndrome Summary. Adam M, Ardinger H, Pagon R, Walace S, Bean L, Mirza G, et al., editors. GeneReviews [Internet]; 2015. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/"},{"issue":"3","key":"key20220420083155_B12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10143-019-01089-1","article-title":"Malignant transformation of craniofacial fibrous dysplasia: a systematic review of overall survival","volume":"43","author":"Li","year":"2020","unstructured":"12 Li Z, Raynald, Wang Z, Qian H. Malignant transformation of craniofacial fibrous dysplasia: a systematic review of overall survival. Neurosurg Rev. 2020;43(3):911-21.","journal-title":"Neurosurg Rev"},{"issue":"5","key":"key20220420083155_B13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00223-019-00550-z","article-title":"Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review","volume":"104","author":"Hartley","year":"2019","unstructured":"13 Hartley I, Zhadina M, Collins MT, Boyce AM. Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review. Calcif Tissue Int. 2019;104(5):517-29.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"key20220420083155_B14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000369","article-title":"Malignant transformation in monostotic fibrous dysplasia: Clinical features, imaging features, outcomes in 10 patients, and review","volume":"94","author":"Qu","year":"2015","unstructured":"14 Qu N, Yao W, Cui X, Zhang H. Malignant transformation in monostotic fibrous dysplasia: Clinical features, imaging features, outcomes in 10 patients, and review. Medicine (Baltimore). 2015;94(3):e369.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"key20220420083155_B15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","unstructured":"15 Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683-92.","journal-title":"J Clin Invest"},{"key":"key20220420083155_B16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1359\/jbmr.06s222","article-title":"Medical therapy in adults with fibrous dysplasia of bone","author":"Chapurlat","year":"2006","unstructured":"16 Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006;21 Suppl 2:114-9.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"key20220420083155_B17","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1359\/jbmr.070511","article-title":"Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome","volume":"22","author":"Hart","year":"2007","unstructured":"17 Hart ES, Kelly MH, Brillante B, Chen CC, Ziran N, Lee JS, et al. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res. 2007;22(9):1468-74.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20220420083155_B18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone","volume":"34","author":"Florenzano","year":"2019","unstructured":"18 Florenzano P, Pan KS, Brown SM, Paul SM, Kushner H, Guthrie LC, et al. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone. J Bone Miner Res. 2019;34(4):653-60.","journal-title":"J Bone Miner Res"},{"key":"key20220420083155_B19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1750-1172-7-S1-S3","article-title":"Pathophysiology and medical treatment of pain in fibrous dysplasia of bone","volume":"24","author":"Chapurlat","year":"2012","unstructured":"19 Chapurlat RD, Gensburger D, Jimenez-Andrade JM, Ghilardi JR, Kelly M, Mantyh P. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet J Rare Dis. 2012;24(7 Suppl 1):S3.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"key20220420083155_B20","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","unstructured":"20 Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub S, Riminucci M, et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab. 2014;99(11):4133-40.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20220420083155_B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/670809","article-title":"Characteristics and Treatment Results of 5 Patients with Fibrous Dysplasia and Review of the Literature","volume":"2015","author":"Ozdemir Kutbay","year":"2015","unstructured":"21 Ozdemir Kutbay N, Sarer Yurekli B, Kartal Baykan E, Baydur Sahin S, Saygili F. Characteristics and Treatment Results of 5 Patients with Fibrous Dysplasia and Review of the Literature. Case Rep Endocrinol. 2015;2015:1-7.","journal-title":"Case Rep Endocrinol"},{"issue":"2","key":"key20220420083155_B22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jbmr.2999","article-title":"Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia","volume":"32","author":"Majoor","year":"2017","unstructured":"22 Majoor BCJ, Appelman-Dijkstra NM, Fiocco M, van de Sande MAJ, Dijkstra PS, Hamdy NAT. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. J Bone Miner Res. 2017;32(2):264-76.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20220420083155_B23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00296-014-3132-x","article-title":"Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction","volume":"35","author":"Wu","year":"2015","unstructured":"23 Wu D, Ma J, Bao S, Guan H. Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction. Rheumatol Int. 2015;35(4):767-72.","journal-title":"Rheumatol Int"},{"issue":"10","key":"key20220420083155_B24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","unstructured":"24 Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997;12(10):1746-52.","journal-title":"J Bone Miner Res"},{"key":"key20220420083155_B25","first-page":"8","article-title":"Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia","author":"Tripathy","year":"2020","unstructured":"25 Tripathy SK, Swaroop S, Velagada S, Priyadarshini D, Das RR, Satpathy AK, et al. Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia. Front Pediatr. 2020;8.","journal-title":"Front Pediatr"},{"issue":"7","key":"key20220420083155_B26","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","unstructured":"26 Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97(7):2272-82.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20220420083155_B27","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.joms.2016.04.001","article-title":"Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw","volume":"74","author":"Metwally","year":"2016","unstructured":"27 Metwally T, Burke A, Tsai JY, Collins MT, Boyce AM. Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2016;74(10):1983-99.","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T12:32:37Z","timestamp":1650457957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/effects-of-zoledronic-acid-therapy-in-fibrous-dysplasia-of-bone-a-single-center-experience\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":27,"alternative-id":["10.20945\/2359-3997000000459"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000459","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}